ABSTRACT
Delayed anaphylaxis after ingestion of red meat because of galactose-alpha-1,3-galactose (alpha-gal) syndrome has increased in recent years. The mechanism involves an immunoglobulin E reaction to alpha-gal, a molecule found in mammalian meat, dairy products, medications and excipients containing mammalian-derived components, and tick salivary glycans. Sensitization occurs due to the bite of a lone star tick and the transmission of alpha-gal molecules into person's bloodstream. We describe a case of alpha-gal syndrome with severe food, drug, and perioperative allergy in which anaphylaxis with hypovolemic shock occurred immediately after an emergency surgical procedure, when a gelatin-containing drug was injected. This case study confirms that the clinical manifestations of alpha-gal syndrome could be different depending on the route of administration, with immediate reactions if an alpha-gal-containing drug is injected and delayed type allergic manifestations occurring several hours after oral intake. The purpose of this report is to highlight the importance of risk communication in case of exposure to medical products and surgical procedures of patients with alpha-gal syndrome and to encourage drug manufacturers to indicate clearly the origin of excipients in product literature.
Subject(s)
Anaphylaxis , Food Hypersensitivity , Shock , Humans , Anaphylaxis/diagnosis , Anaphylaxis/therapy , Anaphylaxis/etiology , Food Hypersensitivity/diagnosis , Food Hypersensitivity/complications , Food Hypersensitivity/immunology , Shock/etiology , Shock/diagnosis , Drug Hypersensitivity/diagnosis , Drug Hypersensitivity/therapy , Male , Animals , Immunoglobulin E/immunology , Excipients/adverse effects , Disaccharides/immunology , Disaccharides/adverse effects , Female , Trisaccharides/immunology , Gelatin/adverse effects , SyndromeSubject(s)
Colonic Neoplasms , Colorectal Neoplasms , Pyrrolidines , Rectal Neoplasms , Thymine , Humans , Bevacizumab/therapeutic use , Trifluridine/therapeutic use , Cost-Benefit Analysis , Colorectal Neoplasms/drug therapy , Colorectal Neoplasms/pathology , Drug Combinations , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Uracil/therapeutic useABSTRACT
BACKGROUND: Over the past few years, major changes have taken place in the treatment of gastroduodenal peptic ulcer. AIM: To evaluate risk factors associated with the incidence of peptic ulcer in inpatients. METHODS: From 2001 to 2004, the number of prescriptions of H2-antagonists and proton pump inhibitors (PPIs) in each department of Verona University Hospital was monitored. Over the same period we prospectively recorded the number of upper endoscopies per department for inpatients with a diagnosis of peptic ulcer. RESULTS: We analyzed 4943 inpatients. A significantly decreasing trend in H(2)-antagonist prescriptions (r=-0,88; P<0.001) and an increasing trend in PPI prescriptions (r=0.97; P<0.001) were observed. The endoscopic incidence of duodenal ulcers decreased linearly from 2001 to 2004 as follows: 6.5% (94/1439) in 2001, 5.6% (82/1473) in 2002, 4.5% (63/1411) in 2003, and 3.1% (22/702) (P<0.001) in 2004. Gastric ulcer incidence, sex, age, indication for endoscopy, use of nonsteroidal anti-inflammatory drugs (NSAIDs), presence of Helicobacter pylori (32%), and smoking and drinking habits showed no significant changes over the study period. Considering time-dependent variables, multivariate regression analysis identified only PPI use and NSAID use as factors predictive of duodenal ulcer but not of gastric ulcer. CONCLUSIONS: In inpatients, PPIs are associated with a reduced risk of duodenal ulcer, whereas NSAIDs are associated with an increased risk. Gastric ulcer was not associated with any increased or degreased risk with the 2 above-mentioned variables.
